Compare Ross Stores, Inc. (ROST) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Sanofi SA — how do they compare? Ross Stores, Inc. trades at $222.41 (market cap $71.94B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and Sanofi SA for 94 Days on average.
| ROST | SNY | |
|---|---|---|
Market Cap | $71.94B | $95.18B |
Volume | 2,002,519 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $52.34 |
52-Week Low | $147.71 | $39.51 |
Typical Hold Time | 48 Days | 94 Days |
Enterprise Value | $72.39B | $114.48B |
Dividend Yield | 0.79% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $222.41, down 1.38% on the day, as technical indicators signal bearish momentum despite strong fundamental performance. The company continues to deliver robust earnings beats with Q2 2026 EPS of $2.66 exceeding expectations of $1.95, while maintaining impressive profitability metrics including 42.63% ROE and 10.85% net income margin. Recent news highlights store expansion initiatives and strong closeout supply positioning the off-price retailer to capture value-conscious consumer demand.
With analyst consensus pointing to 23% upside to the $274.14 price target and 64% buy ratings, ROST presents a compelling growth opportunity despite near-term technical weakness. Key risks include competitive pressures in discount retail and execution challenges in store expansion, but strong cash flow generation and disciplined inventory management support the bullish fundamental case.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
